Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and
Mingchen Ba1, Shuzhong Cui2, Hui Long3
1Intracelom Hyperthermic Perfusion Therapy Center, Cancer Hospital of Guangzhou Medical University, No. 78 Hengzhigang Road, Guangzhou, Guangdong, 510095, People's Republic of China. bamingchen@126.com.
Background:
Bladder hyperthermic intracavitary chemotherapy (HIVEC) has good effectiveness for bladder cancer, but conventional HIVEC systems lack precision and convenient application. To test the safety of a new HIVEC device (BR-TRG-II-type) in pigs and to perform a preliminary clinical trial in patients with bladder cancer.
Methods:
This device was tested on six pigs to optimize the temperature and time parameters. Then, 165 patients (HIVEC after transurethral resection (TUR), n = 128; or HIVEC, n = 37) treated between December 2006 and December 2016 were recruited. Mitomycin C (MMC) was the chemotherapeutic agent. A serum pharmacokinetic study was performed. The primary endpoints were tumor recurrence, disease-free survival (DFS), and cumulative incidence rate (CIR) during follow-up. The adverse effects were graded.
Results:
The animal experiment showed that 45 °C for 1 h was optimal. HIVEC was successful, with the infusion tube temperature stably controlled at about 45 °C, and outlet tube temperature of about 43 °C in all patients, for three sessions. Serum MMC levels gradually increased during HIVEC and decreased thereafter. The mean DFS was 39 ± 3.21 months (ranging from 8 to 78 months), and the DFS rate was 89.1% during follow-up. No adverse events occurred.
Conclusion:
The use of the BR-TRG-II-type HIVEC device is feasible for the treatment of bladder cancer. Future clinical trials in patients with different stages of bladder cancer will further confirm the clinical usefulness of this device.
Trial Registration:
chictr.org.cn: ChiCTR1900022099 (registered on Mar. 252,019). Retrospectively registered.
